Pharmafile Logo
Pharmafocus logo
Advanced Search

sexual health

Showing 5 posts of 5 posts found.

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024
Research and Development GSK, Reproductive health, clinical trial, gonorrhoea, sexual health

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential first-in-class oral antibiotic for the …

News
assorted-condoms

Funding cuts and government inaction has led to soaring STI rates in Britain, new study finds

February 5, 2020
Research and Development AIDS, HIV, STDs, STIs, UK, sexual health

The UK faces a new Sexually Transmitted Infection (STI) diagnoses every 70 seconds, according to a new report that outlines …

News

GSK drops herpes vaccine

October 4, 2010
Research and Development, Sales and Marketing GlaxoSmithKline, Simplirix, herpes, sexual health

Poor phase III results have forced GlaxoSmithKline to halt development of its Simplirix vaccine for women with genital herpes. The …

News
Blog footer

Digital Pharma: UK health clinic first for Pfizer

July 28, 2010
Medical Communications Digital Pharma blog, Pfizer, digital patients, digital pharma med coms, disease awareness campaigns, sexual health

Men in the UK can now go online for confidential advice and information about any health problem through a unique …

News

Bayer Schering’s contraceptive patch enters phase III

May 5, 2009
Research and Development, Sales and Marketing Bayer, sexual health

Bayer Schering is to start phase III trials of its new contraceptive patch and anticipates submitting the product for regulatory …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024